On both clinical and methodologic grounds, this study will have provided a rigorous test of the STA-MCA bypass procedure.
actual entry of both medical and surgical patients.
The trial, funded in 1977 by the U.S. National Institute of Neurological Communicative Disease and Stroke (NINCDS), has been coordinated clinically by a Central Office in the Department of Clinical Neurological Sciences at the University of Western Ontario in London, Ontario and has been coordinated methodologically from a Methods Center in the Department of Clinical Epidemiology and Biostatistics at McMaster University in Hamilton, Ontario. Investigators from these two centers have comprised a Steering Committee which has been responsible for the overall administration and day-to-day execution of the study. Major decisions concerning study policy have been vetted by an Executive Committee consisting of members of the Steering Committee, investigators from participating centers in North America, Europe and the Far East, and representatives from the NINCDS.
A clinical center has been accredited for participation in the trial if it could demonstrate close collaboration between specialists in neurosurgery, neurology, and neuroradiology. Moreover, prior to participation every surgeon was required to demonstrate the achievement of at least 80% graft patency (proven by angiography) on at least 10 consecutive EC/IC procedures on patients with appropriate cerebrovascular lesions.
Annual meetings and workshops have been held in North America, Europe and Asia to bring together clinical investigators, to inform them of the progress of the trial, to resolve any questions concerning its execution, and to maintain a high degree of enthusiasm and collaboration.
The conduct and results of the study have been reviewed twice yearly by a Monitoring Committee appointed by the Stroke and Trauma Program of the NINCDS. 
Methods

Patient Eligibility
To be eligible for the trial, patients have had to satisfy clinical, radiological, and exclusion criteria: a. Clinical Inclusion Criteria:
Patients must have experienced, within three months prior to entry, one or both of the following: (i) transient ischemic attack(s) (TIA) in the carotid distribution (one or more episodes of distinct focal neurological dysfunction or monocular blindness (amaurosis fugax), the symptoms and signs of which cleared completely in less than 24 hours); (ii) minor completed stroke(s) in the carotid distribution (one or more events of distinct focal neurologic dysfunction or amaurosis fugax, the signs of which persisted for more than 24 hours). Patients without useful residual function in the affected territory have not been entered. b. Radiological Inclusion Criteria:
An angiogram demonstrating an atherosclerotic lesion in the appropriate territory has had to be submitted for central confirmation and adjudication by the principal neuroradiologist; bilateral common carotid arteriograms have been requested on all patients, and angiography of the vertebro-basilar circulation has been optional.
One or more of the following atherosclerotic lesions must have been demonstrated in vessels appropriate to the patient's symptoms: (i) stenosis or occlusion of the middle cerebral artery trunk; (ii) stenosis of the internal carotid artery at or above the C2 vertebral body (i.e. inaccessible to carotid endarterectomy); or (iii) internal carotid artery occlusion.
For radiological eligibility, stenosis has been defined as "any recognizable atherosclerotic lesion of the surgically inaccessible portion of the internal carotid artery or middle cerebral artery which, in the opinion of the attending neurosurgeon, might reasonably be expected to benefit from bypass surgery." c. Exclusion Criteria:
Patients have been excluded from the study if they were unable to meet at least the following functional standards: (i) capability of self-care for most activities of daily living (may require some assistance); (ii) retention of some useful residual function in the affected arm or leg; (iii) comprehension intact with no evidence of Wernicke's receptive aphasia; (iv) no, or only mild, motor (expressive, Broca's) aphasia; (v) ability to handle their own oropharyngeal secretions.
Patients also have been excluded from the trial if any of the following pertained: inability to provide informed consent; evidence that the original stroke was due to cerebral hemorrhage; within eight weeks of an acute cerebral ischemic event; exhibition of nonatherosclerotic conditions causing or likely to cause cerebral dysfunction (fibromuscular dysplasia, arteritis, blood dyscrasia, a cardiac source of cerebral emboli, chronic atrial fibrillation, complete heart block, significant valvular heart disease, cardiomyopathy, or nonatherosclerotic dissection); the presence of any morbid condition(s) likely to lead to death within five years (cancer, renal failure (BUN >50 mg%), cardiomegaly (cardiothoracic ratio of >0.50 (>0.55 in Japanese patients), 2 "* or any hepatic or pulmonary disease constituting an unacceptable anesthetic risk); the occurrence of ischemic symptoms isolated to the vertebrobasilar circulation; prior participation in the study (regardless of the occurrence of new ischemic events or success or failure of previous therapy); myocardial infarction within the preceding six months; a fasting blood sugar of 300 mg% or more on the most recent assessment despite appropriate therapy; diastolic blood pressure > 110 mm Hg (using disappearance of sounds for diastolic pressure) despite appropriate medical therapy. Once uncontrolled diabetes or hypertension were corrected, otherwise eligible patients could be entered.
Every entry form has been reviewed by both the Central Office and the Methods Center. All angiograms have been reviewed (without knowledge of the treatment group to which the patient had been randomized) by the principal neuroradiologist at the Central Office. When this review has suggested that an ineligible patient had been entered, an external group of adjudicators (who were not trial participants and were "blind" to the patient's allocation) has reviewed the entry data and angiograms and decided whether the patient should be excluded from the trial, d. Specific Clinical Situations:
Because cerebrovascular disease often involves multiple sites, guidelines for managing, and arbitrary rules for analyzing specific clinical situations have been established. When "tandem lesions" (two lesions in the same vessel or sequence of vessels, one proximal to the other) have existed, and both lesions have fulfilled the entry criteria, the patient has been entered for the more distal lesion. If the proximal lesion has been amenable to endarterectomy, the decisions of whether to perform endarterectomy, and the selection of the initial site for surgery (i.e. endarterectomy or EC/IC bypass), have been left to the judgment of the participating surgeon. In patients judged to require external carotid endarterectomy as a preparation for bypass, it has been recommended that this be performed only after the patient has been randomized to the surgical group. If external carotid endarterectomy had been performed prior to randomization, then 30 days have had to elapse following endarterectomy before the patient could have been entered.
When contralateral carotid disease has existed and has been accessible to endarterectomy, the decision of whether and when to perform contralateral endarterectomy has again been left to the participating neurosurgeon. Once again, if contralateral endarterectomy has been carried out first, 30 days have had to elapse following contralateral endarterectomy before the patient could be entered.
When eligible patients have had appropriate symptoms and angiographic lesions in both carotid distributions, the patient has been entered for the most recent clinically eligible event. If more than one TIA or stroke has occurred prior to entry, the most recent has served as the basis for enrollment.
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In all of the above circumstances, if a 30-day waiting period has applied, the patient was still eligible for randomization, despite the passage of more than three months since the last episode of cerebral ischemia.
Baseline Investigations
At entry, detailed neurological and medical histories and examinations have been carried out and recorded on standardized forms. The examination has included a 12-item functional status assessment in which the patient's ability to perform activities of daily living such as eating, toileting, and ambulation have been rated on a three-point scale: 1. able to perform task without difficulty; 2. able to perform task with difficulty; or 3. unable to perform task without mechanical or personal assistance. Additional historical data have been gathered about employment status, history of diabetes mellitus, hypertension, angina pectoris, myocardial infarction, intermittent claudication, cardiac surgery or other serious illness, current medications, and smoking habits. The patient's blood pressure, heart rate and rhythm, cardiac murmurs, and neck bruits have been recorded. Finally, the following baseline investigations have been carried out: hemoglobin; platelet count; prothrombin time; random blood glucose; blood urea nitrogen; cholesterol; electrocardiogram (for left ventricular hypertrophy, new or old myocardial infarction and rhythm); chest x-ray to estimate the cardiothoracic ratio; and, if available, a computerized tomographic (CT) scan of the head.
Random Allocation to Therapy
If the patient has been judged eligible on clinical and radiographic grounds, informed consent has been requested. If obtained, a tentative date for surgery has been booked (to minimize the time interval between randomization and surgery) and the Methods Center has been contacted by telephone for registration and random allocation (for logistic reasons, a separate randomization center has been set up in Kyoto, Japan, for patients from Japan and Taiwan). To ensure balance between the medical and surgical limbs of this trial, a stratified randomization has been carried out. The strata have been defined by the underlying vascular lesion (stenosis or occlusion of the middle cerebral or internal carotid artery), the presence or absence of a related neurologic deficit and, in the case of patients with internal carotid occlusion, whether related symptoms have occured since its angiographic demonstration (some centers have joined the trial with a commitment to exclude patients with no symptoms since their internal carotid occlusions were demonstrated). Then, based on a computer-generated randomization scheme established at the Methods Center for each participating center and stratum, the patient has been assigned to either the medical or surgical limb of the trial.
Treatment
Patients randomized to the surgical limb have undergone microsurgical, end to side, anastomosis of the superficial temporal or occipital artery to a cortical branch of the middle cerebral artery. All participating surgeons have agreed to follow an identical procedure in the performance of the extra-to intracranial bypass, but minor variations in the surgical technique have been permitted and left to the individual surgeon's discretion.
Because previous randomized trials have established the efficacy of aspirin in patients with TIA and minor stroke, 6 all patients (both medical and surgical) have been prescribed acetylsalicylic acid 325 mg q.i.d. throughout the trial, unless contraindicated or not tolerated. Furthermore, the control of hypertension has been stressed and monitored in both medical and surgical patients; the treatment of other risk factors has been left to individual clinical judgment.
Follow-up
All patients (both medical and surgical) have been examined by a participating neurologist six weeks after randomization and at three-month intervals thereafter (surgical patients have received an additional review approximately 30 days following surgery). At each visit, an interim history has been obtained and a detailed neurologic examination has been performed, including the functional status assessment. In addition, repeat assessments have been made of the patient's employment status, medical and smoking history, medications, blood pressure and cardiac status.
Surgical patients have undergone postoperative angiography; the recommended timing has been three to six months following bypass. All the post-operative angiograms have been reviewed by the principal neuroradiologist at the Central Office. The success of the anastomosis has been assessed by the following features: the comparative size (smaller; same; or larger) of the superficial temporal artery proximal to the anastomosis on preoperative and postoperative angiograms; the degree of retrograde flow in the middle cerebral circulation (none; slight; to the middle cerebral artery bifurcation; or to the internal carotid) and the number of branches of the middle cerebral artery filled. Overall flow through the bypass has been estimated as: none, slight, moderate, good, or excellent. Further followup angiograms have been recommended when the first post-operative angiogram has suggested poor bypass function.
A random sample of 20 preoperative and 20 postoperative angiograms have been reviewed a second time by the principal neuroradiologist (who had been blinded to his original report) to assess intraobserver agreement.
Other medical problems, medications and perioperative complications have been monitored to detect unexpected adverse effects of any medical and/or surgical treatment that patients have undergone during the trial.
Withdrawals and Crossovers
Only patients who refused to continue under observation were to have been withdrawn from the trial; all others were to be retained. EC/IC surgery on the side opposite to the qualifying lesion and internal carotid endarterectomy on either side have been discouraged; however, patients who have undergone these additional procedures have not been withdrawn from the trial. A second EC/IC bypass on the same side has been permitted in a small number of surgical patients in whom it has appeared likely to improve bypass function; however, these surgical procedures have not, by themselves, constituted events, and such patients have not been withdrawn.
Patients who initially accepted their randomization to medical therapy but later underwent EC/IC bypass on the randomized side, or patients who accepted randomization to surgical therapy and then declined the operation were labelled "crossovers". Strokes occurring to such patients before their crossover are to be charged to the medical limb and the surgical limb respectively in the primary analysis. Those who had no events prior to the crossover were judged to have been randomized improperly and to have failed to give proper informed consent. They were considered as one of the exclusion categories.
Events
The main study events are the occurrence of fatal or nonfatal stroke following randomization. However, in order to include any excess perioperative risk, deaths from all causes have been included if they occurred between randomization and 30 days following EC/IC bypass among surgical patients and for a comparable duration among patients in the medical group.
Events have been identified and classified in one or 
The best current means for diagnosis (including CT scan where available) have been used to differentiate strokes due to infarction from those due to hemorrhage. The severity of the stroke, in terms of the impairment of functional status, has been rated on a 10-point scale, using information derived from the neurologic follow-up forms. This Stroke Severity Scale is summarized in table 1.
Transient ischemic attacks, other major cardiovascular morbidity and deaths from non-cerebrovascular causes have also been recorded but have not constituted main events. Thorough documentation has been sought for every death from any cause, including: autopsy findings; emergency room, operative and hospital discharge reports; death certificates; and the observations of any witnesses.
Adjudication of Events
Adjudication of the cause of death and the occurrence and severity of strokes has been performed independently by a neurologist and a neurosurgeon who have not cared for patients in the study and have been blind both to the patients' treatments and to each other's judgments. Disagreements between the two adjudicators have been resolved by consensus. Disagreements between the adjudicators' consensus and the results of the Central Office's Weekly Clinical Reviews have been resolved through discussions with the principal clinical investigators.
Sample Size and Interim Analyses
The required sample size and duration of follow-up initially had been determined on the basis of data available when the protocol had been designed (February 1977) . The following estimates and specifications have been employed: (1) For medically-treated patients: an expected combined stroke and stroke-death rate of 23.6% over five years. 7 "
10
(2) For surgically-treated patients: an estimated 30-day perioperative stroke and death rate of 4%, followed by a 50% reduction in the subsequent rate of fatal and non-fatal stroke compared with medically-treated patients, for a net surgical benefit of 33% reduction in the five-year risk of fatal and non-fatal stroke. It has been agreed that this degree of risk reduction constituted a clinically important surgical benefit which, if achieved in the trial, would justify advocating the EC-IC bypass procedure. (3) A risk of 5% of drawing the false-positive conclu-
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sion that surgery is beneficial when, in truth, it is not (alpha = 0.05, one-tailed). (4) A 10% risk of drawing the false-negative conclusion that surgery is no better than medical therapy when, in truth, surgery results in the clinically important benefit stated above (beta = 0.10; power = 90%). These considerations had required a sample size of 442 patients per treatment group, followed for an average of five years. Allowing for drop-outs, an initial total sample size target of 1,000 patients had been established.
By February 1981, 35% of trial patients had been entered with internal carotid artery occlusion without further ischemic symptoms since angiography. Because this group had been thought to be at a lower risk of subsequent stroke, it had been feared that large numbers of such cases might have obscured a surgical benefit to other patients. This situation was discussed by Executive Committee members who were blind with respect to events in both treatment groups, and they proposed to increase the total sample size target to 1,400 patients. This proposal was accepted by the Monitoring Committee and was implemented.
In order to discharge the ethical responsibility of stopping the trial as soon as a clear cut conclusion is evident, the accumulating data have been analyzed at six-month intervals. An "alerting" procedure has been developed and adopted that calls for the early stopping of the study to have been considered if two consecutive interim analyses have shown either that the surgically treated group are faring significantly better (at the p = 0.02 level) or that it has become very unlikely that any surgical benefit could have been demonstrated. 12 The results of these interim analyses, known only to the principal epidemiologic investigator and chief biostatistician at the Methods Center, have been summarized and reported to the Monitoring Committee.
Appropriate allowance has been made for the statistical effect of these interim challenges of the data; if the trial has not been terminated early, ap-value of 0.04 or less would have constituted statistical significance in the final analysis.
Results
Entry Characteristics
Seventy-one centers, on three continents, have entered a total of 1495 patients between August 1977 and September 1982. The review of entry documentation by the Central Office and Methods Center, supported by an independent review by external adjudicators, has led to the exclusion of 118 (7.9%) of these patients who, usually on the basis of pre-randomization data, have failed to meet all entry criteria. The reasons for these exclusions appear in table 2. An additional ten patients in the surgical group and nine in the medical group have died or experienced a stroke or a major medical disorder (such as pulmonary embolism) that has prevented them from receiving their assigned treatment; however, these patients have remained in the study, and their events have been charged to the group to which they were randomized. Of the 1,377 eligible patients, 714 (52%) have been randomized to medical and 663 (48%) to surgical therapy. Randomization has created balanced treatment groups with respect to both important prognostic characteristics (table 3) and underlying vascular lesions  (table 4) . There have been no striking differences between the two treatment groups for any of these features. Over 70% of trial patients have had abnormal neurological findings at entry, but the majority have had little or no functional impairment (table 5) . [Minor impairment means difficulty in performing (but not in need of external assistance for) any activity of daily living in: swallowing, self-care (feeding, dressing, personal hygiene), ambulation, communication or comprehension]. Major impairment means a loss of independence in one or more of the above activities of daily living, but not of sufficient severity to preclude entry into the trial). Again, the balance between medical and surgical groups has been excellent.
As expected, there have been regional differences in the site of vascular lesions, as shown in table 6. Internal carotid occlusion has been more common in North American and European patients while disease of the middle cerebral arteries has been present in more than 50% of Asian patients, who also have exhibited more tandem lesions.
Some manifestations of atherosclerosis, such as coronary and peripheral vascular disease, have been more common among North American patients (table  7) . There have been no differences, however, in the rates of prior cerebral vascular disease among patients from the three regions.
Surgical Performance
The only data currently available for release on surgical performance concern patency rates following the •Definitions: MCA = Middle cerebral artery; ICA = internal carotid artery; Stenosis = recognizable atherosclerotic lesion (see Methods section, "Radiological Inclusion Criteria"); Tandem lesions = more than one atherosclerotic lesion in the same vessel or sequence of vessels, one proximal to the other. bypass procedure; a patency rate of 95% has been achieved. The agreement between duplicate interpretations of pre-and post-operative angiograms has been high, and will be reported elsewhere.
Patient Follow-Up
No patients have been withdrawn from the trial, and only 2 patients have been lost to follow-up. Reproducibility studies, to be published elsewhere, have demonstrated high agreement in the application of the functional status assessment and stroke severity scales.
Center Performance
The number of eligible patients entered per center has varied considerably, with 21% of the 71 centers having contributed 50% of the study patients. Because this variation in patient entry from center to center has raised the possibility that technical expertise may also vary from center to center, the bypass graft patency rates for small centers (entering less than 25 patients each) have been compared with those for large centers (entering 25 or more patients). These patency rates have been identical (95% and 96%, respectively).
Graft patency rates have also been examined for regional differences. They have been equally high in all three regions: 92% in North America, 94% in Europe and 97% in Asia.
Discussion
The International Cooperative Study of Extracranial/Intracranial Arterial Bypass is the first randomized trial of the EC/IC bypass procedure. Patient entry has been completed. Highly competent neurosurgical, neurological and neuroradiological teams from around the world have recruited and fully documented the clinical state of a sufficient number of appropriate patients to test the value of the bypass procedure in a rigorous fashion. The surgical procedure has been executed in a randomized half of these patients with technical success, as demonstrated by very high graft patency rates. No patients have withdrawn from the trial, and only 1 has been lost to follow-up. Thus, whatever the result of the final analysis, it should be both bias-free and of direct applicability to patients similar to those who participated.
In addition to information concerning the clinical value of the EC/IC bypass procedure, the study will provide new information on several other important topics. For example, the cohort of patients assigned to medical therapy will provide valuable information about the clinical course and prognosis of both middle cerebral artery stenosis and occlusion and internal carotid artery stenosis and occlusion, as well as determining whether there are any important geographic differences in the course of cerebrovascular disease. Furthermore, the detailed review of pre-and post-operative angiograms should identify features that predict success in the prevention of future stroke and stroke-related death. Finally, the three-monthly assessment of the functional status of patients should reveal the quality of life experienced by patients with these varieties of cerebrovascular disease as well as whether this quality is affected by surgery.
Comparisons between this trial and previous investigations of the EC/IC bypass procedure are scientifically tenuous; these earlier studies were not controlled trials, involved fewer patients, and usually included non-consecutive patients with a far wider variety of cerebrovascular conditions (including moyamoya disease, fibromuscular hyperplasia, and venous stasis retinopathy). Nonetheless, in the only previous series in which there is sufficient published data to permit comparison, 13 the patients are remarkably similar to those in the present trial. For example, 80% of Sundt and colleagues' patients are males, with an average age of 55 years, and internal carotid artery occlusion is present in 62%; in patients randomized to surgery in the present trial, 81 % are males, with an average age of 57 years, and 59% have ICA occlusion. Thus, the patients entered into this trial may be closely comparable to analogous patients seen in clinical centers not participating in the study.
The superficial temporal artery to middle cerebral artery anastomosis procedure is an elegant result of modern technology and a testimonial to the sophistication of modern surgical expertise. Although measurements of cerebral blood flow and metabolism suggest that the EC/IC bypass works as a conduit, they cannot determine whether the benefits of the procedure outweigh its risks or whether it is superior to medical management.
14 Given the extraordinary variability in the clinical course of cerebrovascular disease, these TABLE 6 Region* 
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